Inhaler preference appeared to vary by age, with pDMI used by more patients aged 75 years and older, and DPI used by more patients aged 40 to 60 years. Patients with asthma and chronic obstructive ...
"Smart Inhalers Market by Product (Inhalers and Nebulizers), Indication (Asthma and COPD), and Distribution channel (Hospital Pharmacies and Retail Pharmacies): Global Opportunity Analysis and ...
The health regulator has cleared the drug's use as an add-on treatment for some adults with inadequately controlled chronic obstructive pulmonary disease (COPD), a condition that progressively ...
Other companies are rushing to the space with prospective COPD medicines. Two weeks ago, GSK reported that its respiratory blockbuster Nucala plus inhaled maintenance therapy lowered the rate of ...
Poor treatment of asthma and COPD puts a huge burden on the NHS. For example, £1 billion is spent on asthma treatment in the UK each year and represents 60,000 to 65,000 hospital admissions. In ...
evaluated the efficacy and safety of dupilumab for 935 patients aged 40 to 85 years with uncontrollable COPD and type 2 inflammation taking the maximal standard-of-care inhaled therapy (triple ...